| Bioactivity | PROTAC LZK-IN-1 (Compound 21A) is a PROTAC that targets the degradation of LZK (Leucine Zipper Kinase, encoded by MAP3K13). PROTAC LZK-IN-1 (10 μM) promotes the degradation of LZK and inhibits the expression of p53 and c-MYC, leading to reduced viability of global head and neck squamous cell carcinoma (HNSCC) cell lines. PROTAC LZK-IN-1 can be used in cancer research. PROTAC LZK-IN-1 consists of an E3 ligase ligand (blue part, HY-112078), a target protein ligand (red part, HY-170596), and a linker (black part, HY-W019543)[1]. |
| CAS | 2763268-64-8 |
| Formula | C51H64F2N10O5S |
| Molar Mass | 967.18 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Funk AL, et al. Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth. bioRxiv [Preprint]. 2024 Nov 20:2024.11.19.623840. |
PROTAC LZK-IN-1
CAS: 2763268-64-8 F: C51H64F2N10O5S W: 967.18
PROTAC LZK-IN-1 (Compound 21A) is a PROTAC that targets the degradation of LZK (Leucine Zipper Kinase, encoded by MAP3K1
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.